RNAC vs. PHAR, SPRY, NBTX, UPB, SYRE, RAPP, SANA, BCAX, CRON, and RLAY
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Pharming Group (PHAR), ARS Pharmaceuticals (SPRY), Nanobiotix (NBTX), Upstream Bio (UPB), Spyre Therapeutics (SYRE), Rapport Therapeutics (RAPP), Sana Biotechnology (SANA), Bicara Therapeutics (BCAX), Cronos Group (CRON), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.
Cartesian Therapeutics vs. Its Competitors
Pharming Group (NASDAQ:PHAR) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.
Pharming Group presently has a consensus target price of $30.00, indicating a potential upside of 110.66%. Cartesian Therapeutics has a consensus target price of $40.00, indicating a potential upside of 319.51%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Pharming Group.
In the previous week, Pharming Group had 5 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 9 mentions for Pharming Group and 4 mentions for Cartesian Therapeutics. Pharming Group's average media sentiment score of 0.71 beat Cartesian Therapeutics' score of 0.62 indicating that Pharming Group is being referred to more favorably in the media.
Cartesian Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -2.19%. Cartesian Therapeutics' return on equity of 0.00% beat Pharming Group's return on equity.
Pharming Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pharming Group has higher revenue and earnings than Cartesian Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cartesian Therapeutics beats Pharming Group on 10 of the 16 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RNAC) was last updated on 10/14/2025 by MarketBeat.com Staff
